An observational study in Periodontitis and Obesity, sponsored by Gazi University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Gazi University · Observational
Obesity and periodontitis are chronic inflammatory diseases that share common pathological mechanisms. Asprosin, a novel adipokine discovered in 2016, has not been extensively studied in relation to periodontal tissues. In our study, we investigate the levels of asprosin in both serum and gingival crevicular fluid of patients with obesity and those of normal weight who have periodontitis. Additionally, our research aims to clarify the pathophysiological mechanisms linking periodontitis and obesity by examining local and systemic levels of TNF-α, IL-6, and asprosin, alongside clinical periodontal parameters.
71 studies on the registry are indexed under Marfan Syndrome; 16 are open to participants now.
This study's enrollment of 60 is below the median of 119 across 40 observational studies indexed under Marfan Syndrome.
Browse Marfan Syndrome studies →Gazi University is the lead sponsor of 531 studies on the registry; 99 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients were recruited from the Periodontology Clinic at Gazi University Faculty of Dentistry between August 2023 and August 2024. All participants who met the inclusion criteria were included in the study. Before their participation, the study's purpose and methods were explained, and written informed consent was obtained.
Weight classification:
Periodontal health status:
For individuals with periodontitis:
Exclusion Criteria:
Patients with diabetes, defined by:
Other: Participants are not assigned an intervention as part of the study.
Other: Participants are not assigned an intervention as part of the study.
Other: Participants are not assigned an intervention as part of the study.
Other: Participants are not assigned an intervention as part of the study.
Participants are not assigned an intervention as part of the study.
Biyomarker levels
All groups' GCF and serum levels of asprosin, TNF-α, and IL-6 levels
Time frame: 08.10.2023-08.10.2024
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gazi University